US FDA panel rejects maintenance use of OSI/Roche's Tarceva
This article was originally published in Scrip
Executive Summary
The US FDA's oncologic drugs advisory panel has rejected a maintenance indication for OSI Pharmaceuticals/Roche's EGFR-targeted small molecule drug Tarceva (erlotinib) in non-small cell lung cancer (NSCLC).